Literature DB >> 19733854

Evaluation of the psychometric properties and the clinical feasibility of a Chinese version of the Doloplus-2 scale among cognitively impaired older people with communication difficulty.

Yi-Heng Chen1, Li-Chan Lin, Roger Watson.   

Abstract

BACKGROUND: Several behaviourally observed tools have been developed to assess pain among cognitively impaired older people with communication difficulty. However, no adequate pain observation instrument is available for this group in Taiwan.
OBJECTIVE: The study was undertaken to translate the French version of the Doloplus-2 scale into Chinese and to evaluate the psychometric properties and the clinical feasibility of the translated instrument.
DESIGN: A prospective, descriptive design was used. SETTINGS: Five dementia special care units in the Northern Taiwan were used. PARTICIPANTS: Two hundred and forty-one residents with dementia and 14 registered nurses in charge of these residents were recruited.
METHODS: The Doloplus-2 scale was translated into Chinese using the back-translation technique and pilot testing was performed to determine the comprehensibility and the initial psychometric characteristics. Internal consistency and inter-rater reliability were evaluated by Cronbach's alpha and intra-class correlation coefficient, respectively. Based on the known correlated validity model, the association between C-Doloplus-2 and empirically supported correlates of pain such as the past pain history, the presence of pain related condition, functional disability, agitation and depression were examined using Pearson's correlation coefficient for validating the construct validity. Furthermore, factor structure was investigated using Principal Components Analysis.
RESULTS: The internal consistency was adequate for the total scale (alpha 0.74) and the subscales (alpha range 0.67-0.87). The intra-class correlation coefficient of the total scale was 0.81 and of the subscales ranged from 0.60 to 0.81. The association between pain latent variable and disability or depression was demonstrated, partially supporting the construct validity. Three factors were extracted to confirm the original three-dimensional structure perfectly, accounting 65% of the total variance.
CONCLUSIONS: The psychometric qualities of Chinese Doloplus-2 were supported. Further research is needed to assess the clinical value of the translated scale performed in the institutions.

Entities:  

Mesh:

Year:  2009        PMID: 19733854     DOI: 10.1016/j.ijnurstu.2009.06.011

Source DB:  PubMed          Journal:  Int J Nurs Stud        ISSN: 0020-7489            Impact factor:   5.837


  5 in total

1.  Validation of Doloplus-2 among nonverbal nursing home patients--an evaluation of Doloplus-2 in a clinical setting.

Authors:  Karin Torvik; Stein Kaasa; Øyvind Kirkevold; Ingvild Saltvedt; Jacob C Hølen; Peter Fayers; Tone Rustøen
Journal:  BMC Geriatr       Date:  2010-02-20       Impact factor: 3.921

Review 2.  Instruments for assessing pain in persons with severe dementia.

Authors:  Natália Lindemann Carezzato; Gabriela Gallego Valera; Francisco Assis Carvalho Vale; Priscilla Hortense
Journal:  Dement Neuropsychol       Date:  2014 Apr-Jun

Review 3.  Measurement properties, feasibility and clinical utility of the Doloplus-2 pain scale in older adults with cognitive impairment: a systematic review.

Authors:  Hanne Marie Rostad; Inger Utne; Ellen Karine Grov; Martine Puts; Liv Halvorsrud
Journal:  BMC Geriatr       Date:  2017-11-02       Impact factor: 3.921

Review 4.  Psychometric properties of pain measurements for people living with dementia: a COSMIN systematic review.

Authors:  Toby O Smith; Karmen Harvey
Journal:  Eur Geriatr Med       Date:  2022-05-27       Impact factor: 3.269

5.  Psychometric evaluation of the Persian version of the Doloplus-2 (P-Doloplus-2) scale in elderly with dementia

Authors:  Mohammad Zare; Zahra Tagharrobi; Khadijeh Sharifi; Zahra Sooki; Javad Abolhasani
Journal:  Turk J Med Sci       Date:  2020-06-23       Impact factor: 0.973

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.